Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 183   

Articles published

PFE 29.15 -0.42 (-1.42%)
price chart
Should Pfizer Inc. Buy Actavis plc?
Earlier this year, a media circus erupted over Pfizer's reported interest in AstraZeneca (NYSE: AZN ) . The deal would have exceeded $100 billion and created a company roughly the same size as Johnson & Johnson. AstraZeneca brass, however, felt the ...
Pfizer-Actavis Merger Still A Possibility  Bidness ETC
Pfizer Said to Approach Actavis to Gauge Interest in Deal  Bloomberg
Related articles »  
Pfizer drug effective in patients with rare lung cancer, study shows
Pfizer Inc's Xalkori, which treats lung cancer patients with a specific gene mutation, proved effective in shrinking tumors in those with an even rarer form of the disease, according to data presented at a medical meeting on Saturday.
Pfizer Inc. Stock Fails To Break Out: Is It Headed Back Down?
Pfizer Inc. (NYSE: PFE) shareholders have experienced the short-term euphoria of seeing their stock rally a massive 10 percent from August to September.
Related articles »  
Better Dividend Stock: Johnson & Johnson or Pfizer, Inc?
According to Susanna Kim of ABC News, dividend yield and dividend growth comprised 90% of the total nominal returns for investors in the S&P 500 between 1910 and 2010.
Why I'd Avoid Pfizer Inc. Stock Despite the Dividend
Pfizer's problem in the clinic is uncertainty regarding its ability to generate new blockbuster drugs. The company decided, along with almost every other Big Pharma simultaneously, to go after novel oncology and high cholesterol drugs to replace former ...
Related articles »  
Pfizer Announces Positive Data For Cancer Drug Xalkori
Pfizer Inc. (PFE) announced extended Phase I trial results for Xalkori (crizotinib) at the European Society for Medical Oncology (ESMO) meeting on Saturday.
Pfizer's Lung Cancer Drug Helps Patients With Gene Defect  Bloomberg
Pfizer's lung cancer drug Xalkori helps treat 72 percent of patients ...  WallStreet OTC
Related articles »  
Can Pfizer Grow Without A Big Acquisition?
While Pfizer may shift its sights to another big acquisition, valuations may be stretched and smaller portfolio acquisitions may be more attractive.
Pfizer Inc. (NYSE:PFE) Acquires InnoPharma, Inc. For $225 million Upfront ...  USMarketsDaily
Pfizer Inc.'s (NYSE:PFE) New Acquisition Will Strengthen Injectable' ...  eMarketsDaily
Related articles »  
GlycoMimetics In The Red After Pfizer Delays Trial
GlycoMimetics, Inc. (GLYC) stock closed down more than 14% on the Nasdaq today, after the company said its licensing partner, Pfizer Inc. (PFE), has delayed initiating a phase 3 trial of Rivipansel (GM-1071). Rivipansel, the most advanced pipeline ...
Pharma Stock Updates - GlycoMimetics Inc (NASDAQ:GLYC), Pfizer Inc. (NYSE ...  Equities Focus (registration)
GlycoMimetics Announces a Delay in the Initiation of the Phase 3 Trial With ...  MarketWatch
Related articles »  
Pfizer Inc.: Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology ...
NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Kyowa Hakko Kirin (Tokyo:4151), announced today that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer's PF-05082566, ...
Stocks Reaction on News: Dominion Resources, Inc. (NYSE:D), Pfizer Inc ...  eMarketsDaily
Volatile Stocks to Watch-Micron Technology, Inc. (NASDAQ:MU), Pfizer Inc ...  Techsonian (press release)
Related articles »  
Stocks Alert: Pfizer Inc. (NYSE:PFE), Angie's List Inc (NASDAQ:ANGI), Oncomed ...
Pfizer Inc. (NYSE:PFE) and Kyowa Hakko Kirin said late on Monday they signed an agreement to study the therapeutic potential of combining Pfizer's PF-05082566 antibody with Kyowa Hakko Kirin's anti-CCR4 antibody mogamulizumab in a Phase Ib clinical ...